Immuron Limited (IMC.AX)
AUD 0.08
(-3.7%)
AUD 0.08
(-3.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -5.8 Million AUD | 3.32% |
| 2023 | -6 Million AUD | -47.82% |
| 2022 | -4.05 Million AUD | 51.76% |
| 2021 | -8.41 Million AUD | -148.17% |
| 2020 | -3.39 Million AUD | 27.99% |
| 2019 | -4.7 Million AUD | -45.02% |
| 2018 | -3.24 Million AUD | 61.32% |
| 2017 | -8.39 Million AUD | -1.55% |
| 2016 | -8.26 Million AUD | -93.01% |
| 2015 | -4.28 Million AUD | -51.02% |
| 2014 | -2.83 Million AUD | 12.51% |
| 2013 | -3.24 Million AUD | 1.87% |
| 2012 | -3.3 Million AUD | -14.32% |
| 2011 | -2.88 Million AUD | -27.59% |
| 2010 | -2.26 Million AUD | 23.77% |
| 2009 | -2.97 Million AUD | 25.59% |
| 2008 | -3.99 Million AUD | 13.24% |
| 2007 | -4.6 Million AUD | -5.27% |
| 2006 | -4.37 Million AUD | -71.06% |
| 2005 | -2.55 Million AUD | -21.7% |
| 2004 | -2.09 Million AUD | 0.0% |
| 2003 | - AUD | 100.0% |
| 2002 | -1.9 Million AUD | 0.68% |
| 2001 | -1.91 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -8.62 Million AUD | -43.72% |
| 2024 Q2 | -3.75 Million AUD | 0.0% |
| 2024 Q4 | -3.78 Million AUD | 0.0% |
| 2023 FY | -6 Million AUD | -47.82% |
| 2023 Q2 | -3.41 Million AUD | 0.0% |
| 2023 Q4 | -2.58 Million AUD | 0.0% |
| 2022 Q4 | -1.73 Million AUD | 0.0% |
| 2022 Q2 | -2.34 Million AUD | 0.0% |
| 2022 FY | -4.05 Million AUD | 51.76% |
| 2021 Q2 | -5.4 Million AUD | 0.0% |
| 2021 FY | -8.41 Million AUD | -148.17% |
| 2021 Q4 | -3 Million AUD | 0.0% |
| 2020 Q2 | -2.58 Million AUD | 0.0% |
| 2020 FY | -3.39 Million AUD | 27.99% |
| 2020 Q4 | -1.56 Million AUD | 0.0% |
| 2019 FY | -4.7 Million AUD | -45.02% |
| 2019 Q4 | -3.32 Million AUD | 0.0% |
| 2019 Q2 | -1.58 Million AUD | 0.0% |
| 2018 Q4 | 28.48 Thousand AUD | 0.0% |
| 2018 Q2 | -3.27 Million AUD | 0.0% |
| 2018 FY | -3.24 Million AUD | 61.32% |
| 2017 Q4 | -4.18 Million AUD | 0.0% |
| 2017 FY | -8.39 Million AUD | -1.55% |
| 2017 Q2 | -4.21 Million AUD | 0.0% |
| 2016 Q4 | -4.43 Million AUD | 0.0% |
| 2016 Q2 | -3.83 Million AUD | 0.0% |
| 2016 FY | -8.26 Million AUD | -93.01% |
| 2015 Q4 | -2.91 Million AUD | 0.0% |
| 2015 Q2 | -1.37 Million AUD | 0.0% |
| 2015 FY | -4.28 Million AUD | -51.02% |
| 2014 Q2 | -1.43 Million AUD | 0.0% |
| 2014 FY | -2.83 Million AUD | 12.51% |
| 2014 Q4 | -1.27 Million AUD | 0.0% |
| 2013 Q3 | -810.3 Thousand AUD | 42.52% |
| 2013 FY | -3.24 Million AUD | 1.87% |
| 2013 Q1 | -825.74 Thousand AUD | 0.0% |
| 2013 Q4 | -1.83 Million AUD | -126.03% |
| 2013 Q2 | -1.4 Million AUD | -70.71% |
| 2012 Q1 | -722.32 Thousand AUD | 0.0% |
| 2012 FY | -3.3 Million AUD | -14.32% |
| 2012 Q4 | -825.74 Thousand AUD | 0.0% |
| 2012 Q3 | -825.74 Thousand AUD | 0.0% |
| 2012 Q2 | -825.74 Thousand AUD | -14.32% |
| 2011 Q3 | -722.32 Thousand AUD | 0.0% |
| 2011 Q4 | -722.32 Thousand AUD | 0.0% |
| 2011 FY | -2.88 Million AUD | -27.59% |
| 2011 Q2 | -722.32 Thousand AUD | -27.59% |
| 2011 Q1 | -566.11 Thousand AUD | 0.0% |
| 2010 Q3 | -566.11 Thousand AUD | 0.0% |
| 2010 FY | -2.26 Million AUD | 23.77% |
| 2010 Q4 | -566.11 Thousand AUD | 0.0% |
| 2010 Q2 | -566.11 Thousand AUD | 23.77% |
| 2010 Q1 | -742.62 Thousand AUD | 0.0% |
| 2009 FY | -2.97 Million AUD | 25.59% |
| 2009 Q1 | -998.04 Thousand AUD | 0.0% |
| 2009 Q2 | -742.62 Thousand AUD | 25.59% |
| 2009 Q3 | -742.62 Thousand AUD | 0.0% |
| 2009 Q4 | -742.62 Thousand AUD | 0.0% |
| 2008 Q1 | -1.15 Million AUD | 0.0% |
| 2008 Q2 | -998.04 Thousand AUD | 13.24% |
| 2008 FY | -3.99 Million AUD | 13.24% |
| 2008 Q4 | -998.04 Thousand AUD | 0.0% |
| 2008 Q3 | -998.04 Thousand AUD | 0.0% |
| 2007 Q1 | -1.09 Million AUD | 0.0% |
| 2007 FY | -4.6 Million AUD | -5.27% |
| 2007 Q2 | -1.15 Million AUD | -5.27% |
| 2007 Q4 | -1.15 Million AUD | 0.0% |
| 2007 Q3 | -1.15 Million AUD | 0.0% |
| 2006 Q2 | -1.09 Million AUD | -71.06% |
| 2006 Q1 | -638.81 Thousand AUD | 0.0% |
| 2006 Q4 | -1.09 Million AUD | 0.0% |
| 2006 Q3 | -1.09 Million AUD | 0.0% |
| 2006 FY | -4.37 Million AUD | -71.06% |
| 2005 Q2 | -638.81 Thousand AUD | -21.7% |
| 2005 FY | -2.55 Million AUD | -21.7% |
| 2005 Q4 | -638.81 Thousand AUD | 0.0% |
| 2005 Q3 | -638.81 Thousand AUD | 0.0% |
| 2005 Q1 | -524.91 Thousand AUD | 0.0% |
| 2004 FY | -2.09 Million AUD | 0.0% |
| 2004 Q2 | -524.91 Thousand AUD | 0.0% |
| 2004 Q3 | -524.91 Thousand AUD | 0.0% |
| 2004 Q4 | -524.91 Thousand AUD | 0.0% |
| 2004 Q1 | - AUD | 0.0% |
| 2003 Q1 | -476.13 Thousand AUD | 0.0% |
| 2003 Q2 | - AUD | 100.0% |
| 2003 Q3 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | 100.0% |
| 2002 Q1 | -479.41 Thousand AUD | 0.0% |
| 2002 Q4 | -476.13 Thousand AUD | 0.0% |
| 2002 Q3 | -476.13 Thousand AUD | 0.0% |
| 2002 Q2 | -476.13 Thousand AUD | 0.68% |
| 2002 FY | -1.9 Million AUD | 0.68% |
| 2001 Q3 | -479.41 Thousand AUD | 0.0% |
| 2001 Q4 | -479.41 Thousand AUD | 0.0% |
| 2001 Q2 | -479.41 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | -1.91 Million AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 159.703% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -297.575% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 2.309% |
| Biome Australia Limited | -1.91 Million AUD | -203.209% |
| Patrys Limited | -3.53 Million AUD | -63.913% |
| Orthocell Limited | -11.68 Million AUD | 50.338% |
| Imugene Limited | -140.93 Million AUD | 95.884% |
| Noxopharm Limited | -7.53 Million AUD | 23.011% |
| PYC Therapeutics Limited | -38.85 Million AUD | 85.071% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 52.874% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 19.277% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 19.78% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 34.138% |
| CSL Limited | 5.64 Billion AUD | 100.103% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 19.351% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -89.427% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 111.803% |
| Starpharma Holdings Limited | -15.15 Million AUD | 61.732% |
| Nanollose Limited | -1.24 Million AUD | -364.154% |
| Memphasys Limited | -2.7 Million AUD | -114.538% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -171.89% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -182.079% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -31.1% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 60.536% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -101.864% |
| Race Oncology Limited | -13.38 Million AUD | 56.645% |
| Nyrada Inc. | -4.56 Million AUD | -27.208% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 76.851% |
| PharmAust Limited | -6.65 Million AUD | 12.878% |
| Immutep Limited | -44.93 Million AUD | 87.091% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 87.051% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 70.405% |
| BTC Health Limited | 1.05 Million AUD | 649.719% |
| Acrux Limited | -9.83 Million AUD | 41.01% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 102.567% |
| Biotron Limited | -5.15 Million AUD | -12.617% |
| Tissue Repair Ltd | -4.87 Million AUD | -18.974% |
| AdAlta Limited | -5.26 Million AUD | -10.254% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 87.712% |
| Hexima Limited | -1 Million AUD | -475.08% |
| AnteoTech Limited | -11.72 Million AUD | 50.53% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 91.091% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 73.693% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -26.408% |
| Actinogen Medical Limited | -12.83 Million AUD | 54.816% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -2.291% |